Print Page  |  Close Window

Investor Overview

Corporate Profile

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs... Read more

Stock Quote

PTGX (Common Stock)
$11.12 - 0.88 (7.33%)
Exchange :NASDAQ
Volume :70,235
Today's Open$11.98
Previous Close$12.00
Data as of June 27, 2017 4:00 p.m. ET
Refresh quote

Stock Chart

Stock chart for: PTGX.O.  Currently trading at $11.12 with a 52 week high of $26.36 and a 52 week low of $8.00.

Recent Press Releases

June 08, 2017

Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its Board of Directors read more

May 30, 2017

Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease read more

May 25, 2017

Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300 read more

Upcoming Events

There are currently no events scheduled.


Investor Presentation

Data provided by Nasdaq. Minimum 15 minutes delayed.